Apatinib weakens resistance of gastric cancer cells to paclitaxel by suppressing JAK/STAT3 signaling pathway.

Bei, Yanping; Chen, Xue; Xu, Quan; Lv, Jiaming; Hu, Jing; Yang, Shaohui

Bei, Yanping; Chen, Xue; Xu, Quan; Lv, Jiaming; Hu, Jing; Yang, Shaohui.

Afiliação

Bei Y; Department of Radiotherapy, Ningbo Medical Center Lihuili Hospital, Ningbo, China.
Chen X; Department of Radiotherapy, Ningbo Medical Center Lihuili Hospital, Ningbo, China.
Xu Q; Department of Radiotherapy, Ningbo Medical Center Lihuili Hospital, Ningbo, China.
Lv J; Department of Radiotherapy, Ningbo Medical Center Lihuili Hospital, Ningbo, China.
Hu J; Department of Radiotherapy, Ningbo Medical Center Lihuili Hospital, Ningbo, China.
Yang S; Department of Anorectal Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo, China.

Drug Dev Res ; 83(2): 379-388, 2022 04.

Article em En | MEDLINE | ID: mdl-34405891

Assuntos

Neoplasias Gástricas; Linhagem Celular Tumoral; Humanos; Janus Quinases/metabolismo; Janus Quinases/farmacologia; Janus Quinases/uso terapêutico; Paclitaxel/farmacologia; Piridinas; Fator de Transcrição STAT3/metabolismo; Transdução de Sinais; Neoplasias Gástricas/tratamento farmacológico; Neoplasias Gástricas/metabolismo

Palavras-chave

apatinib; gastric cancer; janus-activated kinase 2; paclitaxel-resistance; signal transducer and activator of transcription 3

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas Limite: Humans Idioma: En Revista: Drug Dev Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google